Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.68 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.58 |
| ▸ | RELA | Q04206 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17001367 | 0.92 | DYRK1A (0.74) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL4921069 | 0.90 | MEN1 (0.68) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL4924519 | 0.86 | RAB9A (0.79) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL4922739 | 0.86 | NPC1 (0.79) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL21568266 | 0.84 | NPC1 (0.56) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL4921024 | 0.84 | SMN1; SMN2 (0.72) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL18824223 | 0.83 | DYRK1A (0.64) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL31078954 | 0.83 | CSNK1D (0.60) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL3787846 | 0.82 | DYRK1A (0.76) | NPC1RAB9AKMT2AMEN1DYRK1A | |
| SCHEMBL4921505 | 0.82 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-10231954-B2 | Neurodegenerative therapies | LYTIX BIOPHARMA AS (NO) | 2019-03-19 | — | — | US | disclosed |
| US-20170007583-A1 | Neurodegenerative Therapies | PHARMASUM THERAPEUTICS AS (NO) | 2017-01-12 | — | — | US | disclosed |
| EP-3102202-A1 | NEURODEGENERATIVE THERAPIES | Lytix Biopharma AS (NO) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015118026-A1 | NEURODEGENERATIVE THERAPIES | LYTIX BIOPHARMA AS (NO) | 2015-08-13 | — | — | WO | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231954-B2 | Neurodegenerative therapies | OXSR1, MAPT, TTBK1 | NPC1 425/4885RAB9A 2725/4885KMT2A 3790/4885 |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | NPC1 148/4885RAB9A 3359/4885KMT2A 1905/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | NPC1 148/4885RAB9A 3359/4885KMT2A 1905/4885 |
| US-20170007583-A1 | Neurodegenerative Therapies | OXSR1, MAPT, TTBK1 | NPC1 430/4885RAB9A 2737/4885KMT2A 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.